Development of glucose-responsive 'smart' insulin systems.

Curr Opin Endocrinol Diabetes Obes

aDepartment of Biochemistry and Medical Scientist Training Program bDepartment of Biochemistry cDepartment of Biomedical Engineering dDepartment of Biochemistry eDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Published: August 2017

Purpose Of Review: The complexity of modern insulin-based therapy for type I and type II diabetes mellitus and the risks associated with excursions in blood-glucose concentration (hyperglycemia and hypoglycemia) have motivated the development of 'smart insulin' technologies (glucose-responsive insulin, GRI). Such analogs or delivery systems are entities that provide insulin activity proportional to the glycemic state of the patient without external monitoring by the patient or healthcare provider. The present review describes the relevant historical background to modern GRI technologies and highlights three distinct approaches: coupling of continuous glucose monitoring (CGM) to deliver devices (algorithm-based 'closed-loop' systems), glucose-responsive polymer encapsulation of insulin, and molecular modification of insulin itself.

Recent Findings: Recent advances in GRI research utilizing each of the three approaches are illustrated; these include newly developed algorithms for CGM-based insulin delivery systems, glucose-sensitive modifications of existing clinical analogs, newly developed hypoxia-sensitive polymer matrices, and polymer-encapsulated, stem-cell-derived pancreatic β cells.

Summary: Although GRI technologies have yet to be perfected, the recent advances across several scientific disciplines that are described in this review have provided a path towards their clinical implementation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613292PMC
http://dx.doi.org/10.1097/MED.0000000000000345DOI Listing

Publication Analysis

Top Keywords

delivery systems
8
gri technologies
8
newly developed
8
insulin
6
development glucose-responsive
4
glucose-responsive 'smart'
4
'smart' insulin
4
systems
4
insulin systems
4
systems purpose
4

Similar Publications

Introduction: The effectiveness of pharmaceutical treatment methods is vital in cancer treatment. In this context, various targeted drug delivery systems are being developed to minimize or eliminate existing deficiencies and harms. This study aimed to model the interaction of MEN-based drug-targeting systems with cancer cells and determine the properties of interacting MENs.

View Article and Find Full Text PDF

Aims: This study aimed to develop Imatinib Mesylate (IMT)-loaded Poly Lactic-co-Glycolic Acid (PLGA)-D-α-tocopheryl polyethylene glycol succinate (TPGS)- Polyethylene glycol (PEG) hybrid nanoparticles (CSLHNPs) with optimized physicochemical properties for targeted delivery to glioblastoma multiforme.

Background: Glioblastoma multiforme (GBM) is the most destructive type of brain tumor with several complications. Currently, most treatments for drug delivery for this disease face challenges due to the poor blood-brain barrier (BBB) and lack of site-specific delivery.

View Article and Find Full Text PDF

The article analyses the recent amendment by the National Medical Commission (NMC) in India, capping the number of undergraduate medical seats in high-performing states, which has sparked a debate. With a healthcare system catering to the diverse needs of 1.4 billion people, regional disparities in healthcare personnel distribution have emerged, especially among doctors.

View Article and Find Full Text PDF

Protein nanoparticles as potent delivery vehicles for polycytosine RNA-binding protein one.

World J Diabetes

January 2025

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou 511436, Guangdong Province, China.

Ma recently reported in the that ferroptosis occurs in osteoblasts under high glucose conditions, reflecting diabetes pathology. This condition could be protected by the upregulation of the gene encoding polycytosine RNA-binding protein 1 (PCBP1). Additionally, Ma used a lentivirus infection system to express PCBP1.

View Article and Find Full Text PDF

Currently, no approved antiviral drugs target dengue virus (DENV) infection, leaving treatment reliant on supportive care. DENV vaccine efficacy varies depending on the vaccine type, the circulating serotype, and vaccine coverage. We investigated defective interfering particles (DIPs) and lipid nanoparticles (LNPs) to deliver DI290, an anti-DENV DI RNA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!